Vimarsana
Biggest News Aggregation in the World

Alvogen News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Alvogen. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Alvogen Today - Breaking & Trending Today

BERNAMA - LOTUS, ALVOGEN, NRX PHARMACEUTICALS COLLABORATE TO DEVELOP AND COMMERCIALISE NRX-101 - Vimarsana News

BERNAMA - LOTUS, ALVOGEN, NRX PHARMACEUTICALS COLLABORATE TO DEVELOP AND COMMERCIALISE NRX-101

LOTUS, ALVOGEN, NRX PHARMACEUTICALS COLLABORATE TO DEVELOP AND COMMERCIALISE NRX-101

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101 - Vimarsana News

NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global markets

Appeals Court Affirms Validity of Collegium's Belbuca® Patents - Vimarsana News

Appeals Court Affirms Validity of Collegium's Belbuca® Patents

Ruling bars ANDA filer Alvogen from entering market until 2032 patent expirySTOUGHTON, Mass., Dec. 22, 2022 -- Collegium Pharmaceutical, Inc. , a leading, diversified specialty pharmaceutical... | December 22, 2022

A Powerful Investment Alliance of Aztiq and Innobic Acquires Alvogen's Shares in Lotus and Adalvo in a US$475m Deal - Vimarsana News

A Powerful Investment Alliance of Aztiq and Innobic Acquires Alvogen's Shares in Lotus and Adalvo in a US$475m Deal

The Consortium jointly, through Aztiq II HoldCo, will acquire a 100% stake in Alvogen Emerging Markets Holdings Limited, thereby becoming the leading shareholders in Lotus Pharmaceuticals and Adalvo

Natco Pharma rises after USFDA nod for cancer treatment drug - Vimarsana News

Natco Pharma rises after USFDA nod for cancer treatment drug

Natco Pharma jumped 6.2% to Rs 884.35 after the company received final approval for everolimus tablets in the US market.Natco Pharma announced that its marketing partner, Breckenridge Pharmaceutical Inc. (BPI), has received final approval for its abbreviated new drug application (ANDA) for everolimus tablets (a generic version of Afinitor) from the US Food and Drug Administration (USFDA). BPI plans to launch 2.5 mg, 5 mg and 7.5 mg strengths of the product shortly within the next few weeks. The launch of 10mg strength of the product is subject to confidential terms of a settlement and licen...